
- /
- Supported exchanges
- / US
- / WINT.NASDAQ
Windtree Therapeutics Inc (WINT NASDAQ) stock market data APIs
Windtree Therapeutics Inc Financial Data Overview
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company is also developing AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trials for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its ADS for use in its Phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Windtree Therapeutics Inc data using free add-ons & libraries
Get Windtree Therapeutics Inc Fundamental Data
Windtree Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -24 124 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Windtree Therapeutics Inc News

Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 202...


Istaroxime shows positive results in cardiogenic shock study
WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a clinical-stage biotech company with a market capitalization of $2.17 million, announced Monday that its Phase 2 study of istaroxime for e...

Wondering what's happening in today's after-hours session?
Enable social media cookies to share Wondering what's happening in today's after-hours session? By Mill Chart Last update: Apr 8, 2025 Let's have a look at what is happening on the US markets afte...

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
WARRINGTON, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interve...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.